After many times of buying shares, the major shareholder from Japan has held over 38% of Ha Tay Pharmaceutical shares.
After many times of buying shares, the major shareholder from Japan has held over 38% of Ha Tay Pharmaceutical shares.
Aska Pharmaceutical Co. Ltd. has successfully purchased more than 2.1 million DHT shares of Ha Tay Pharmaceutical JSC during the period from December 3 to December 10, 2024.
After this transaction, the number of shares held by Aska Pharmaceutical increased to 31.4 million shares, equivalent to an increase in ownership ratio from 35.61% to 38.23%.
December 3, 2024 was also the session when DHT shares reached a historical peak when they increased to the ceiling for the second consecutive session to VND 108,300/share. Although the stock later fell into profit-taking, up to now, DHT is still at its highest price since listing.
 |
| DHT stock is at an all-time high. |
With an average price of about 100,000 VND/share, it is estimated that Aska Pharmaceutical has spent about 216 billion VND to increase its ownership ratio at Ha Tay Pharmaceutical.
Increasing the ownership ratio to over 36% means that Aska Pharmaceutical has the necessary veto power over important decisions within the authority of the General Meeting of Shareholders.
Aska Pharmaceutical is known as a long-standing pharmaceutical company in Japan, specializing in the production, trading, import and export of pharmaceuticals and medical equipment. Aska Pharmaceutical has become a strategic shareholder of DHT since 2021 and has continuously increased its ownership ratio in this domestic pharmaceutical company since then and is currently the only major shareholder of Duoc Ha Tay.
On the stock market, DHT shares have seen a strong increase in price in 2024, since May 2024. With the closing price on December 18, 2024 at VND 90,000/share, DHT's market price is 4 times higher than its value at the beginning of this year.
Contrary to the growth in stock price, DHT's business results are going backwards as 9-month profit decreased significantly compared to the same period last year.
Although in the last 3 quarters of 2024, profits increased as the profit of each quarter was higher than the previous quarter, compared to the same period last year, DHT's 9-month profit only reached 54.8 billion VND, down 23%.
The reason comes from the costs increasing more strongly than the revenue growth. DHT's net revenue for the first 9 months still increased slightly, reaching 1,543 billion VND, however, costs, especially business costs, have increased dramatically. Business costs for the first 9 months of this year accounted for more than 80 billion VND, an increase of more than 51% over the same period.
Earlier this year, at the 2024 Annual General Meeting of Shareholders, DHT's 2024 plan was approved with total revenue of VND1,769 billion and pre-tax profit of VND78.5 billion. With pre-tax profit of VND67.9 billion in 9 months, DHT has achieved 86% of the plan.
Regarding room for foreign investors, at the General Meeting of Shareholders, DHT leaders said that the company does not have a specific plan to increase the maximum foreign ownership ratio to over 50%.
DHT also said that the company has worked with its Japanese partner Aska to develop a medium-term plan for 2024-2027, with a vision to 2040, striving to become the first enterprise to produce original branded drugs by 2030.
Source: https://baodautu.vn/co-dong-nhat-ban-manh-tay-mua-gom-co-phieu-duoc-ha-tay-d232962.html
Comment (0)